Nature Communications (Sep 2022)
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
- Marta Palafox,
- Laia Monserrat,
- Meritxell Bellet,
- Guillermo Villacampa,
- Abel Gonzalez-Perez,
- Mafalda Oliveira,
- Fara Brasó-Maristany,
- Nusaibah Ibrahimi,
- Srinivasaraghavan Kannan,
- Leonardo Mina,
- Maria Teresa Herrera-Abreu,
- Andreu Òdena,
- Mònica Sánchez-Guixé,
- Marta Capelán,
- Analía Azaro,
- Alejandra Bruna,
- Olga Rodríguez,
- Marta Guzmán,
- Judit Grueso,
- Cristina Viaplana,
- Javier Hernández,
- Faye Su,
- Kui Lin,
- Robert B. Clarke,
- Carlos Caldas,
- Joaquín Arribas,
- Stefan Michiels,
- Alicia García-Sanz,
- Nicholas C. Turner,
- Aleix Prat,
- Paolo Nuciforo,
- Rodrigo Dienstmann,
- Chandra S. Verma,
- Nuria Lopez-Bigas,
- Maurizio Scaltriti,
- Monica Arnedos,
- Cristina Saura,
- Violeta Serra
Affiliations
- Marta Palafox
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- Laia Monserrat
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- Meritxell Bellet
- Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology
- Guillermo Villacampa
- Oncology Data Science Group, Vall d’Hebron Institute of Oncology
- Abel Gonzalez-Perez
- Institute for Research in Biomedicine (IRB Barcelona)
- Mafalda Oliveira
- Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology
- Fara Brasó-Maristany
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Nusaibah Ibrahimi
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy
- Srinivasaraghavan Kannan
- Bioinformatics Institute (A*STAR)
- Leonardo Mina
- Medica Scientia Innovation Research (MedSIR)
- Maria Teresa Herrera-Abreu
- The Breast Cancer Now Research Centre
- Andreu Òdena
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- Mònica Sánchez-Guixé
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- Marta Capelán
- Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology
- Analía Azaro
- Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology
- Alejandra Bruna
- Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research
- Olga Rodríguez
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- Marta Guzmán
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- Judit Grueso
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- Cristina Viaplana
- Oncology Data Science Group, Vall d’Hebron Institute of Oncology
- Javier Hernández
- Translational Molecular Pathology, Vall d’Hebron Institute of Research (VHIR)
- Faye Su
- Novartis Pharmaceuticals
- Kui Lin
- Genentech, Inc., South San Francisco
- Robert B. Clarke
- Breast Biology Group, Manchester Breast Centre
- Carlos Caldas
- Cancer Research UK
- Joaquín Arribas
- CIBERONC, Vall d’Hebron Institute of Oncology
- Stefan Michiels
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy
- Alicia García-Sanz
- Medica Scientia Innovation Research (MedSIR)
- Nicholas C. Turner
- The Breast Cancer Now Research Centre
- Aleix Prat
- Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Paolo Nuciforo
- Molecular Oncology Group, Vall d’Hebron Institute of Oncology
- Rodrigo Dienstmann
- Oncology Data Science Group, Vall d’Hebron Institute of Oncology
- Chandra S. Verma
- Bioinformatics Institute (A*STAR)
- Nuria Lopez-Bigas
- Institute for Research in Biomedicine (IRB Barcelona)
- Maurizio Scaltriti
- Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
- Monica Arnedos
- Department of Medical Oncology, Gustave Roussy
- Cristina Saura
- Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology
- Violeta Serra
- Experimental Therapeutics Group, Vall d’Hebron Institute of Oncology
- DOI
- https://doi.org/10.1038/s41467-022-32828-6
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 20
Abstract
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
